RecruitingNot ApplicableNCT06276010

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

Use of Nafamostat Mesilate for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation After Cardiac Surgery: Efficacy and Safety


Sponsor

Xiaotong Hou

Enrollment

80 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥ 18 years old
  • VA-ECMO or VV-ECMO was accepted after cardiac surgery.
  • The ECMO treatment team believes that systemic anticoagulation is needed
  • Sign the informed consent form

Exclusion Criteria10

  • The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.
  • Long-term use of anticoagulants before establishment of ECMO
  • Antiplatelet drugs were used before the establishment of ECMO
  • Severe liver insufficiency
  • Connective tissue disease
  • There is a history of allergy to heparin or nemolastat mesylate.
  • Pregnant
  • Previous diagnosis of heparin-induced thrombocytopenia
  • Expect to die within 48 hours
  • ECPR

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGnafamostat mesilate

Use nafamostat mesilate as an anticoagulant

DRUGunfractionated heparin group

Use unfractionated heparin as an anticoagulant


Locations(1)

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06276010


Related Trials